Navigation Links
Neurobiological Technologies Reports Second Quarter Financial Results
Date:2/11/2008

eds. This will support our Phase 3 clinical trials for Viprinex(TM). We are pleased that the investors in this offering included existing shareholders, significant new institutional investors and members of our Board of Directors. We continue to invest in our key asset, Viprinex, for acute ischemic stroke currently in two Phase III clinical trials. We believe Viprinex has the potential to double the treatment window over the current approved drug, while at the same time reducing the major side effects of fibrinolytics, namely, symptomatic intracranial hemorrhage."

Freiman continued: "I am also very pleased Dr. Warren Wasiewski, who joined NTII in February 2007 as Vice President, Clinical Programs was promoted to Chief Medical Officer of NTII with primary responsibility for running the clinical trial program for Viprinex. Dr. Wasiewski is a Board Certified Pediatric Neurologist with an extensive clinical career. Prior to joining NTII, he worked at AstraZeneca where he was Sr. Medical Director of clinical research CNS/Emerging Products. At AstraZeneca, Dr. Wasiewski had responsibility for running the global SAINT trials for AstraZeneca's neuroprotectant drug candidate."

About Viprinex Phase 3 Trial Program

Viprinex is an investigational agent with multiple novel mechanisms of action that appear to have the potential to expand the treatment window for treating acute ischemic stroke with a lower risk of intracranial bleeding. The only approved agent to treat stroke is required to be given within the first three hours of stroke symptoms primarily due to increased bleeding risk beyond that window. This time limit has been a barrier to receiving care and improving outcomes and quality of life for stroke patients. Previous large Phase III trials have demonstrated that Viprinex may be effective and appears to be well tolerated for acute ischemic stroke.

Conference Call Information

NTI will webcast its quarterly financial results and host a
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Neurobiological Technologies Reports Going Concern Qualification
2. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
3. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
6. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
7. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
8. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
9. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. Advanced technologies aim to transform the coaching of top athletes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 Irwin ... launched and directed a hospital-wide Patient Blood Management (PBM) ... that reduced overall blood usage by more than 60 ... , Covered in detail in an article in ... resulted in substantially reduced perioperative red cell loss, less ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Two addiction ... joined Dr. Marissa Pei on a CNBC ... focusing on addiction. Aired on KCAA AM 1050, the ... Duncan, marriage and family therapist, as they discuss current ... to affect more than 23.5 million Americans. The program, ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Synthetic ... According to an article published by International ... marijuana (dubbed K2, Spice, and black mamba) causes ... of these synthetic substances make it nearly impossible ... patients’ use of the substance due to the ...
(Date:5/26/2015)... Indosoft, Inc ., developer of ... DMi Partners contact center to Q-Suite 5.8 call ... contact center ACD system to drop Asterisk 1.4 support. ... trunk features as diversion headers, added Lyra support via ... to warm transfers to improve information handling ...
(Date:5/26/2015)... 26, 2015 i2i Systems, the leader ... more than 15 years, has earned 2014 Patient Centered ... Quality Assurance (NCQA) for its flagship product i2iTracks ... of the work we have done to create healthier ... the acknowledgement from NCQA once again,” said Janice Nicholson, ...
Breaking Medicine News(10 mins):Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 3Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 2Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 3Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3
... Reportedly Claims the Life of a Pop Icon , , ... in grieving the loss of pop icon Michael Jackson. His apparent ... SCA is a leading cause of death worldwide. , ... cardiac arrest is not uncommon," said Bobby Khan, MD, Chairman of ...
... number of deaths and injuries associated with Hawaiian air tours ... according to a new study by researchers from the Johns ... and Policy. However, the proportion of crashes that resulted ... to an increase in crashes that resulted from poor visibility, ...
... DETROIT, June 25 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... at the request of the Food and Drug Administration, ... Michigan facilities. The seizure also included ingredients held at ... Caraco,s Detroit facility, completed in May 2009, found unresolved ...
... Calif., June 25 A U.S. District Court judge ... halt a proposed $2 cut in wages for the state,s 400,000 ... cuts in all California counties that were planning on passing the ... , The injunction, issued by federal judge Claudia Wilken, was in ...
... Inc., maker of BladderScan(R) bladder volume instruments and ... Kendall Stever as Chief Financial Officer ("CFO"). ... of the Company,s global financial affairs, including day ... Washington State, taxation, investor relations as well as ...
... mind,s eye, an arm or hand changes shape, study finds, ... club and your brain may do more than look for an ... tools to be extensions of the body. , The mere act ... of a subject,s arm," said Lucilla Cardinali, a graduate student in ...
Cached Medicine News:Health News:Sudden Cardiac Arrest Foundation Mourns the Loss of Michael Jackson 2Health News:Sightseeing helicopter crashes in Hawaii decrease following FAA regulations 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action 2Health News:Verathon Inc. Appoints Kendall Stever as Chief Financial Officer 2Health News:Grab a Tool and Change Your Brain 2
(Date:5/26/2015)...  EndoChoice today announced the launch of its initial ... which will represent 25.6% of its outstanding common stock ... corporation in connection with the offering. The initial ... $15 and $17 per share. The underwriters for the ... up to an additional 937,500 shares of EndoChoice common ...
(Date:5/26/2015)... LONDON , May 26, 2015 ... that technology,s commercial potential ,What,s the future of ... and commercial predictions from 2015. Stay ahead there ... tests, you explore sales results, R&D, opportunities and ... visiongain shows you what,s possible for ...
(Date:5/26/2015)... , May 26, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in New York City. The public is welcome ... on the Array BioPharma website.Event: Jefferies 2015 Global ... 2015Time:1:30 p.m. Eastern Time Webcast: www.arraybiopharma.com  About Array ...
Breaking Medicine Technology:EndoChoice Announces Launch of Its Initial Public Offering 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 3Cell-Based Assays: World Industry and Market Prospects 2015-2025 4Cell-Based Assays: World Industry and Market Prospects 2015-2025 5Cell-Based Assays: World Industry and Market Prospects 2015-2025 6Cell-Based Assays: World Industry and Market Prospects 2015-2025 7
... WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.,(OTCBB: ... that new,data presented at an international influenza ... line outperforms,current cell technologies at replicating human ... step towards the production of,a cell-culture based ...
... of patients receiving highest dose,achieves A1c with ... /PRNewswire-FirstCall/ -- According to,findings presented today at ... Association (ADA) in Chicago, Illinois, the,investigational treatment ... analog under development by Novo Nordisk for ...
Cached Medicine Technology:HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
... to remove a cast from an arm or ... patients are cut or burned by the cast ... professionals to remove any cast with confidence. This ... cuts and burns from the cast saw and ...
... choice plays an important part in ... particularly where reduced capsule formation, inflammation ... considerations. GORE-TEX Suture, a nonabsorbable, ePTFE ... characteristics sought by a variety of ...
... GORE-TEX ACUSEAL Cardiovascular Patch ... it to "seal" around penetrating ... bleeding by as much as ... with improved suture retention, multi-directional ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
Medicine Products: